Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04492020 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 518
- Enrollment target
NCT04492020 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 518 participants.
The verdict
NCT04492020, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 518 participants
- Enrollment target
Study Summary
Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome
Interventions
- DRUG Placebo
- DRUG Ubrogepant 100 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 518 participants |
| Start Date | 2020-08-21 |
| Est. Completion | 2022-04-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04492020
The ClinicalTrials.gov registry entry for NCT04492020 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 518 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04492020 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04492020 about?
NCT04492020 is a clinical study titled "Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants". Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome
What is the current status of trial NCT04492020?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 518 participants. The study started on 2020-08-21. Estimated completion is 2022-04-19.
What interventions are being tested in trial NCT04492020?
The interventions under investigation include: Placebo (DRUG), Ubrogepant 100 mg (DRUG).
Who is sponsoring clinical trial NCT04492020?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.